|Day Low/High||42.82 / 43.27|
|52 Wk Low/High||37.81 / 45.58|
Here is a look at two big pharma stalwarts to determine the better stock to buy for growth and income.
These stocks could be toxic to your portfolio in the month ahead.
Oil bounces back, German producer price data point to a continued low inflation outlook.
GlaxoSmithKline (GSK) named Emma Walmsley, the company's head of consumer healthcare, as CEO beginning next March.
Wells Fargo CEO John Stumpf will apologize Tuesday to the bank's customers in Senate testimony; U.S. stock futures are rising; GlaxoSmithKline names a new CEO.
Oil prices fall, taking shares in the sector down with them, while German producer price data point to a continued low inflation outlook.
SoftBank is one of 4 stocks to fire up your portfolio, says ASTON/Pictet portfolio manager Benjamin Beneche.
A strong performance from the ViiV Healthcare venture and a foreign-exchange booster make the case for the U.K.'s leading pharmaceuticals business.
The Consumer Union is alleging that Mylan may have paid Teva to withhold its EpiPen competitor from the market.
GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ:INVA) today announced the presentation of further data from the pivotal phase III FULFIL study with investigational closed triple combination therapy fluticasone...
GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ:INVA) today announced that the results from the pioneering Salford Lung Study (SLS) have been published in the New England Journal of Medicine (NEJM).
Investors once OK with waiting patiently for a Gilead rebound are growing frustrated, even angry, at the company's lack of progress.
GlaxoSmithKline (GSK) is working on a two-pill HIV regimen that could potentially change the standard of HIV treatment and push it ahead of rival pharmaceutical companies.
London based investment manager warns of further falls in U.K dividends.
Which stocks will be most favored by the corporate-bond purchases?
Parents, young adults urged to educate themselves about meningitis B, responsible for one-third of U.S. cases
This market is like a leaky helium balloon; watch out for sudden downdrafts.
Two companies, one a tech giant and the other a Big Pharma stalwart, have formed a joint venture that's bringing disruptive technology to new drug development.
This big pharma blue chip is on a growth trajectory that often eludes companies of its massive size.
The Google parent and Big Pharma major have announced a joint venture into the developing world of bioelectronics treatments.
GlaxoSmithKline's (GSK) Dr. Slaoui believes the company's partnership with Alphabet (GOOGL) will create new nano devices to treat chronic diseases.
The pharmaceutical giant is teaming up with Google's parent with as much as $715 million in joint investments.
GlaxoSmithKline and Google's parent Alphabet announced their joint plan to pioneer a new form of electronic medical treatment.
Uber reaches an agreement for its China operations to be acquired by local rival Didi Chuxing; Fed's Dudley says don't rule out rate hike this year; U.S. stock futures rise.
The companies will invest $715 million over seven years to develop miniature implantable devices to help chronic diseases.
CEO Soriot says the company's pipeline is progressing well, and predicts a boost to full-year earnings from a decline in the pound.